| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Capital expenditures | 0 | 0 | 0 |
| Proceeds from sanuwave convertible note receivable | 0 | 0 | - |
| Net cash provided by investing activities | 0 | 0 | 0 |
| Proceeds from warrants and short-term debt - related parties | 0 | 0 | 0 |
| Proceeds from issuance of short-term debt - unaffiliated | 0 | 0 | 0 |
| Repayments of short-term debt unaffiliated | 0 | 0 | 0 |
| Payment of sepa commitment fee | 0 | 0 | 0 |
| Proceeds from pipe offering, net of offering costs | 0 | 0 | 0 |
| Tax withholding on vesting of restricted stock units | - | 0 | - |
| Proceeds from sale of common stock in private placement | 1,035 | 2,460 | 2,460 |
| Proceeds from sale of common stock and warrants in private placement | 2,000 | - | - |
| Proceeds from related party note | 6,812 | - | - |
| Proceeds from exercise of stock options | 108 | - | - |
| Proceeds from merchant cash advance | 2,286 | - | - |
| Proceeds from merchant cash receivable | - | 891 | - |
| Repayment from merchant cash advance | 1,069 | - | - |
| Repayment of merchant cash advance | - | 221 | - |
| Proceeds received from exercise of warrants pursuant to dragasac inducement agreement | 2,460 | - | - |
| Repayments of short-term debt - related parties | - | 77 | 42 |
| Repayment of short-term debt related party | 113 | - | - |
| Tax withholding on vesting of restricted stock units | 190 | 112 | 98 |
| Proceeds from the sale of common stock in pipe offering | - | 1,010 | - |
| Repayment of related party notes | 5,900 | - | - |
| Net cash provided by financing activities | 7,429 | 3,951 | 2,320 |
| Issuance of common stock to palantir as consideration for settlement agreement | 0 | 0 | 0 |
| Issuance of common stock relating to yorkville for debt extension and sepa commitment fee | 0 | 0 | 0 |
| Other, net | 0 | 0 | 0 |
| Accrued r&d software | 0 | 0 | 0 |
| Net loss | -67,354 | -44,278 | -19,754 |
| Depreciation and amortization | 5,492 | 3,668 | 1,834 |
| Non cash lease expense | 87 | 61 | 32 |
| Provision for inventory obsolescence | - | -37 | -123 |
| Provision for credit losses | -151 | -53 | -61 |
| Change in fair value of warrant liabilities | 5,298 | 1,034 | -242 |
| Reduction in inventory reserve for obsolescence | 40 | - | - |
| Loss on issuance of common stock to yorkville in connection with the side letter | 382 | 382 | 149 |
| Loss on issuance of common stock in connection with the settlement of debt | 72 | 72 | 51 |
| Issuance of warrants for services | 788 | 317 | - |
| Loss on issuance of convertible note with warrants | -2,335 | - | - |
| Gain on forgiveness of interest | 991 | - | - |
| Stock-based compensation expense | 7,126 | 5,085 | 2,637 |
| Issuance of common stock as compensation expense for consulting services | 108 | 108 | - |
| Loss on extinguishment of debt | -6,356 | -5,736 | -5,736 |
| Change in fair value of debt | 1,911 | 1,087 | 12 |
| Non cash interest expense | 4,749 | 3,782 | 2,451 |
| Accounts receivable | -7,003 | -2,458 | 1,350 |
| Inventory | -8,521 | -6,214 | -2,550 |
| Prepaid expenses and other assets | 301 | -47 | -251 |
| Accounts payable | 1,291 | 1,104 | 17 |
| Accrued expenses and other liabilities | 9,757 | 8,935 | 2,709 |
| Lease liabilities - operating | 258 | 169 | 83 |
| Deferred revenue | -797 | 117 | 25 |
| Amortization of licensing obligation | 51 | - | - |
| Net cash used in operating activities | -8,151 | -3,992 | -2,993 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -722 | -41 | -673 |
| Cash and cash equivalents at beginning of period | 10,977 | - | - |
| Cash and cash equivalents at end of period | 10,255 | - | - |
Celularity Inc (CELUW)
Celularity Inc (CELUW)